Date: 2016-02-08
Type of information: R&D agreement
Compound: EB66® cell line for the development of EB66®-based Influenza vaccines
Company: GSK (UK) Valneva (France)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism: EB66® cell line is a highly efficient platform for vaccine production. It is derived from duck embryonic stem cells and today represents a compelling alternative to the use of chicken eggs for large scale manufacturing of human and veterinary vaccines. To date, Valneva has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies to utilize its EB66® technology. The first human vaccine using EB66® technology received marketing approval in 2014 and the first veterinary vaccine in 2012.
Disease: influenza
Details: * On February 8, 2016, Valneva announced that it has signed a new R&D collaboration agreement with GSK for the development of EB66®-based influenza vaccines. Under the agreement, Valneva will conduct an R&D program on behalf of GSK to develop and improve upstream processes which will serve for the manufacturing of influenza
vaccines based on Valneva’s EB66® cell line.
The program received the full support of the US Department of Health and Services (HHS) which encourages the development of new vaccine technologies in order to prevent and treat diseases including Influenza through its dedicated arm, the Biomedical Advanced Research and Development Authority (BARDA). In the frame of this collaboration contract between GSK and Valneva, BARDA will oversee and finance part of the advanced development program.
Financial terms: In May 2007, Valneva granted an exclusive commercial license to GSK to develop and market worldwide pandemic and seasonal human Influenza vaccines using Valneva’s EB66® cell line. Under the 2007 agreement, Valneva is entitled to receive milestone payments as well as royalties associated with future sales. Under this new collaboration agreement, Valneva also secured additional research fees.
Latest news:
